Suresh Katti
Plus aucun poste en cours
Profil
Suresh Katti worked as a Director of Protein Sciences at Alexion Pharmaceuticals, Inc., a Director of Drug Discovery & Design at Optherion, Inc., and a Vice President of Research at Gemini Therapeutics, Inc. He holds a doctorate degree from the Indian Institute of Science.
Anciens postes connus de Suresh Katti
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Optherion, Inc.
 Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | Corporate Officer/Principal | - |
| GEMI THER | Chief Tech/Sci/R&D Officer | - |
Formation de Suresh Katti
| Indian Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Optherion, Inc.
Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
